We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VERAPAMIL LU/ VERAPAMIL LRX (Luminarie Pty Ltd)
Product name
VERAPAMIL LU/ VERAPAMIL LRX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
147 (255 working days)
Active ingredients
Verapamil hydrochloride
Registration type
New generic medicine
Indication
Tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in WPW syndrome, see SECTION 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE), atrial flutter with rapid conduction, extrasystoles.
For the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline (epinephrine) in halothane anaesthesia, respectively.
Acute hypertension.
Acute coronary insufficiency.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine